Publications récentes
= Texte intégral disponible
- Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada
BMC Health Services Research. 2011; [Epub ahead of print]
Tony M, Wagner M, Khoury H, Rindress D, Papastavros T, Oh P, Mireille Goetghebeur - Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): Applying the EVIDEM framework to medicines appraisal
Medical Decision Making 2011; [Epub ahead of print]
Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D - Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation
American Journal of Cardiology. 2011;108(1):151-61.
Ogilvie I, Welner S, Cowell W, Lip G - Ischemic stroke and bleeding rates in 'real-world' atrial fibrillation patients
Thromb Haemost. 2011;106(1):34-44.
Ogilvie I, Welner S, Cowell W, Lip G - Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in Europe show under-utilisation of preventive therapies
Thromb Haemost. 2011;106(4):1-9.
Khoury H, Welner S, Kubin M, Folkerts K, Haas S - Economic burden of herpes zoster among skilled nursing facility residents in the US
Journal of the American Medical Directors Association 2011; [Epub ahead of print]
Ma L, White R, Narayanan S, Schmader MD - Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis
Rheumatol Int 2011; [Epub ahead of print]
Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Yoshinaga T, Freundlich B, Suzukawa M - Burden of rotavirus gastroenteritis in the Middle Eastern and North African pediatric population
BMC Infectious Diseases 2011;11(9):1-11.
Khoury H, Ogilvie I, El Khoury A, Yinghui D, Goetghebeur M - Burden of rotavirus gastroenteritis in the pediatric population in central and eastern Europe: serotype distribution and burden of illness
Human Vaccines 2011;7(5):523-33.
Ogilvie I, Khoury H, El Khoury A, Goetghebeur M - Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice
Clinical and Experimental Rheumatology 2011;29(1):26-34.
Moots R, Haraoui B, Matucci-Cerinic N, van Riel PL, Kekow J, Schaeverbeke T, Davis A, Tedeschi M, Freundlich B, Chang DJ, Singh A - Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis
Rheumatology 2010;50(2):401-09.
Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A - Health-related quality of life and healthcare resource use in European patients with plaque psoriasis: an association independent of observed disease severity
Clinical and Experimental Dermatology 2010 Jun 21;36(1):24-8.
Sato R, Milligan G, Molta C, Singh A - Underuse of oralanticoagulants in atrial fibrillation: a systematic review
The American Journal of Medicine 2010;123(7):638-45.
Ogilvie I, Newton N, Welner S, Cowell W, Lip G - Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decisionmaking framework to growth hormone for Turner syndrome patients
Cost Effectiveness and Resource Allocation 2010;8(1):4.
Goetghebeur M, Wagner M, Khoury H, Rindress D, Gregoire J-P, Deal C - Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial
Annals of the Rheumatic Diseases 2010;69(1):222-225.
Kekow J, Moots R, Emery P, Durez P, Koenig A, Singh A, Pedersen R, Robertson D, Freundlich B, Sato R - The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics
Journal of the European Academy of Dermatology and Venereology 2010 May;24(5):548-54.
Christophers E, Barker JNWN, Griffiths CEM, Dauden E, Milligan G, Molta C, Sato R, Boggs R - Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients
Journal of Gastroenterology and Hepatology 2009;25(5):892-8.
Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Kumada H - The ISPOR Good Practices for Quality Improvement of Cost-effectiveness Research Task Force Report
Value in Health 2009;12(8)
McGhan WF, Maiwenn A, Doshi JA, Kamae I, Marx SE, Rindress D - Venous leg ulcers: patient concordance with compression therapy and its impact on healing and prevention of recurrence
International Wound Journal 2009;6(5):386-93.
Moffatt C, Kommala D, Dourdin N, Choe Y - Cost-effectiveness of atorvastatin 10 mg daily in the primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada
Canadian Journal of Diabetes 2009;33(4):363-74.
Khoury H, Wagner M, Merikle E, Johnson SJ, Roberts C - Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: A systematic review of conclusions and assumptions
Vaccine 2009;27(36):4891-904.
Ogilvie I, El Khoury A, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M - Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis
Arthritis & Rheumatism 2009;61(11):1592-600.
Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, Strand V, vanVollenhoven RF - Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada
Canadian Journal of Clinical Pharmacology 2009;16(2):e331-e345.
Wagner M, Goetghebeur M, Pandya A, Merikle E, Chu P, Taylor DCA - Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial
Canadian Journal of Cardiology 2009;25(11):e362-e369.
Wagner M, Lindgren P, Merikle E, Goetghebeur M, Jonsson B - Worksite health promotion: the value of the Tune Up Your Heart program
Population Health Management 2009;12(6):297-304.
Chung M, Melnyk P, Blue D, Renaud D, Breton M-C
- Detection of Cognitive Impairment and Dementia Using the Animal Fluency Test: the DECIDE Study
Canadian Journal of Neurological Sciences 2009;36(5):599-604.
Sebaldt RJ, Dalzeil W, Massoud F, Tanguay A, Ward R, Thabane L, Melnyk P, Landry P, Lescrauwaet B - Post-marketing surveillance of the safety and effectiveness of etanercept in Japan
Journal of Rheumatology 2009:36(5);898-906.
Koike T, Harigai M, Inokuma S, Ishiguro N, Inoue K, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Freundlich B, Suzukawa M